131 related articles for article (PubMed ID: 28332899)
1. In Vitro Tests for Aerosol Deposition. V: Using Realistic Testing to Estimate Variations in Aerosol Properties at the Trachea.
Wei X; Hindle M; Delvadia RR; Byron PR
J Aerosol Med Pulm Drug Deliv; 2017 Oct; 30(5):339-348. PubMed ID: 28332899
[TBL] [Abstract][Full Text] [Related]
2.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
3. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition.
Delvadia RR; Longest PW; Hindle M; Byron PR
J Aerosol Med Pulm Drug Deliv; 2013 Jun; 26(3):145-56. PubMed ID: 23025452
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Tests for Aerosol Deposition. IV: Simulating Variations in Human Breath Profiles for Realistic DPI Testing.
Delvadia RR; Wei X; Longest PW; Venitz J; Byron PR
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):196-206. PubMed ID: 26447531
[TBL] [Abstract][Full Text] [Related]
5. Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.
Longest PW; Tian G; Khajeh-Hosseini-Dalasm N; Hindle M
J Aerosol Med Pulm Drug Deliv; 2016 Dec; 29(6):461-481. PubMed ID: 27082824
[TBL] [Abstract][Full Text] [Related]
6. A dry powder inhaler with reduced mouth-throat deposition.
Wang ZL; Grgic B; Finlay WH
J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
[TBL] [Abstract][Full Text] [Related]
7. An Exploration of Factors Affecting
Ruzycki CA; Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
[No Abstract] [Full Text] [Related]
8. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
Worth Longest P; Hindle M
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):99-112. PubMed ID: 18956950
[TBL] [Abstract][Full Text] [Related]
9. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique.
Bur M; Huwer H; Muys L; Lehr CM
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):119-27. PubMed ID: 20073555
[TBL] [Abstract][Full Text] [Related]
10. Nebulization and
Mišík O; Kejíková J; Cejpek O; Malý M; Jugl A; Bělka M; Mravec F; Lízal F
Mol Pharm; 2024 Apr; 21(4):1848-1860. PubMed ID: 38466817
[TBL] [Abstract][Full Text] [Related]
11. Effects of flow pattern, device and formulation on particle size distribution of nebulized aerosol.
Hu J; Zhang R; Beng H; Deng L; Ke Q; Tan W
Int J Pharm; 2019 Apr; 560():35-46. PubMed ID: 30664994
[TBL] [Abstract][Full Text] [Related]
12. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
Olsson B; Borgström L; Lundbäck H; Svensson M
J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
[TBL] [Abstract][Full Text] [Related]
13. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
Munzel U; Marschall K; Fyrnys B; Wedel M
Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
[TBL] [Abstract][Full Text] [Related]
14. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
15. Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.
de Boer AH; Hagedoorn P; Gjaltema D; Goede J; Frijlink HW
Int J Pharm; 2006 Mar; 310(1-2):81-9. PubMed ID: 16442246
[TBL] [Abstract][Full Text] [Related]
16. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
Cheng YS; Fu CS; Yazzie D; Zhou Y
J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657
[TBL] [Abstract][Full Text] [Related]
17. Short inhalation exposures of the isolated and perfused rat lung to respirable dry particle aerosols; the detailed pharmacokinetics of budesonide, formoterol, and terbutaline.
Ewing P; Eirefelt SJ; Andersson P; Blomgren A; Ryrfeldt A; Gerde P
J Aerosol Med Pulm Drug Deliv; 2008 Jun; 21(2):169-80. PubMed ID: 18518793
[TBL] [Abstract][Full Text] [Related]
18. Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers.
Ruzycki CA; Murphy B; Nathoo H; Finlay WH; Martin AR
Pharm Res; 2020 Sep; 37(10):209. PubMed ID: 32995953
[TBL] [Abstract][Full Text] [Related]
19. In vitro/in vivo comparisons in pulmonary drug delivery.
Newman SP; Chan HK
J Aerosol Med Pulm Drug Deliv; 2008 Mar; 21(1):77-84. PubMed ID: 18518834
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of enhanced condensational growth (ECG) for controlled respiratory drug delivery in a mouth-throat and upper tracheobronchial model.
Hindle M; Longest PW
Pharm Res; 2010 Sep; 27(9):1800-11. PubMed ID: 20454837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
